Ixico Regulatory News (IXI)

4 Nov 2005 12:47

Phytopharm PLC04 November 2005 NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY OR CONNECTED PERSONS This form is intended for use by an issuer to make a RIS notification requiredby DR 3.1.4R(1). (1) An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24. (2) An issuer making a notification in respect of a derivative relating to the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24. (3) An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24. (4) An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. Please complete all relevant boxes in block capital letters. 1. Name of the issuer PHYTOPHARM PLC 2. State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.4R(1)(a); or (ii) DR 3.1.4(R)(1)(b) a disclosure made in accordance with section 324 (as extended by section 328) of the Companies Act 1985; or (iii) both (i) and (ii) NOTIFICATION RELATES TO (I) 3. Name of person discharging managerial responsibilities/director DR RICHARD DIXEY 4. State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person AS 3 ABOVE 5. Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest - 6. Description of shares (including class), debentures or derivatives or financial instruments relating to shares - 7. Name of registered shareholders(s) and, if more than one, the number of shares held by each of them - 8. State the nature of the transaction - 9. Number of shares, debentures or financial instruments relating to shares acquired - 10. Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage) - 11. Number of shares, debentures or financial instruments relating to shares disposed - 12. Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage) - 13. Price per share or value of transaction - 14. Date and place of transaction - 15. Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage) - 16. Date issuer informed of transaction - If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes 17. Date of grant 3 NOVEMBER 2005 18. Period during which or date on which it can be exercised 3 NOVEMBER 2008 TO 2 NOVEMBER 2015 19. Total amount paid (if any) for grant of the option NIL 20. Description of shares or debentures involved (class and number) 32,409 PHYTOPHARM PLC ORDINARY 1 PENCE SHARES 21. Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise ONE PENCE 22. Total number of shares or debentures over which options held following notification 438,473 23. Any additional information PERFORMANCE CRITERIA ARE BASED ON TOTAL SHAREHOLDER RETURN COMPARED TO COMPARATOR GROUPS ON THE THIRD ANNIVERSARY OF GRANT. NO OPTIONS VEST FOR BELOW MEDIAN PERFORMANCE AND 100% VEST FOR UPPER DECILE PERFORMANCE AND ABOVE WITH PRO RATA VESTING BETWEEN MEDIAN AND UPPER DECILE PERFORMANCE. FOR 21,606 OPTIONS THE COMPARATOR GROUP COMPRISES 25 OTHER UK LISTED BIOTECH COMPANIES AND FOR 10,803 OPTIONS THE COMPARATOR GROUP IS THE FTSE SMALL CAP INDEX 24. Name of contact and telephone number for queries DR G W CHONG 01480 437697 Name and signature of duly authorised officer of issuer responsible for making notification DR G W CHONG Date of notification 4 NOVEMBER 2005 This information is provided by RNS The company news service from the London Stock Exchange